AUB ScholarWorks

Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: A retrospective observational study

Show simple item record

dc.contributor.author Sheikh-Taha M.
dc.contributor.author Ghosn S.
dc.contributor.editor
dc.date Oct-2012
dc.date.accessioned 2017-10-05T15:32:48Z
dc.date.available 2017-10-05T15:32:48Z
dc.date.issued 2012
dc.identifier 10.1177/0897190012442721
dc.identifier.isbn
dc.identifier.issn 08971900
dc.identifier.uri http://hdl.handle.net/10938/15401
dc.description.abstract Background: Anticoagulation therapy during percutaneous coronary intervention (PCI) has been the focus of numerous clinical trials. Low-anticoagulant doses have been successfully used in patients undergoing elective PCI, a situation with low-thrombogenic milieu. Objective: The purpose of the study was to evaluate the safety and efficacy of shorter duration of treatment with bivalirudin in patients undergoing elective PCI and receiving optimal antiplatelet therapy. Methods: We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0.75 + 1.75 mg-kg per h for the duration of PCI; n = 197) or a reduced bivalirudin dose (IV bolus of 0.75 mg-kg; n = 200). Results: Procedural success was obtained in 100percent of cases. The primary end point (in-hospital death, acute myocardial infarction, or need for urgent target vessel revascularization) did not differ between both the groups (6 patients [3percent] in the conventional dose group vs 5 patients [2.5percent] in the reduced dose group). Major bleeding occurred in 1 patient in the conventional dose group (P = nonsignificant [NS]). Minor bleeding occurred in 4 patients (2percent) in the conventional dose group vs 5 patients (2.5percent) in the reduced dose group (P = NS) and was mainly due to bleeding at entry site. Conclusion: In patients undergoing elective PCI, using bivalirudin as a bolus only dosing may be as effective and less costly when compared with bolus followed by an infusion for the duration of the intervention. A larger study is needed to confirm our findings. © The Author(s) 2012.
dc.format.extent
dc.format.extent Pages: (537-540)
dc.language English
dc.relation.ispartof Publication Name: Journal of Pharmacy Practice; Publication Year: 2012; Volume: 25; no. 5; Pages: (537-540);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: A retrospective observational study
dc.type Article
dc.contributor.affiliation Sheikh-Taha, M., Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, POBox 36, Byblos, Lebanon
dc.contributor.affiliation Ghosn, S., Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.authorAddress Sheikh-Taha, M.; Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, POBox 36, Byblos, Lebanon; email: marwantaha@yahoo.com
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Dermatology;
dc.contributor.authorDepartment Dermatology
dc.contributor.authorDivision
dc.contributor.authorEmail
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited
dc.description.citedCount
dc.description.citedTotWOSCount
dc.description.citedWOSCount
dc.format.extentCount 4
dc.identifier.articleNo
dc.identifier.coden JPPRE
dc.identifier.pubmedID 22572222
dc.identifier.scopusID 84866676874
dc.identifier.url
dc.publisher.address
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr
dc.relation.ispartOfIssue 5
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Journal of Pharmacy Practice
dc.relation.ispartofPubTitleAbbr J. Pharm. Pract.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 25
dc.source.ID
dc.type.publication Journal
dc.subject.otherAuthKeyword antithrombotic
dc.subject.otherAuthKeyword bivalirudin
dc.subject.otherAuthKeyword percutaneous coronary intervention
dc.subject.otherChemCAS abciximab, 143653-53-6
dc.subject.otherChemCAS acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1
dc.subject.otherChemCAS clopidogrel, 113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8
dc.subject.otherChemCAS eptifibatide, 148031-34-9
dc.subject.otherChemCAS hirulog, 128270-60-0
dc.subject.otherChemCAS Antithrombins
dc.subject.otherChemCAS Aspirin, 50-78-2
dc.subject.otherChemCAS Hirudins
dc.subject.otherChemCAS
dc.subject.otherIndex abciximab
dc.subject.otherIndex acetylsalicylic acid
dc.subject.otherIndex clopidogrel
dc.subject.otherIndex eptifibatide
dc.subject.otherIndex hirulog
dc.subject.otherIndex acute heart infarction
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex article
dc.subject.otherIndex bleeding
dc.subject.otherIndex cardiovascular disease
dc.subject.otherIndex controlled study
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug safety
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex mortality
dc.subject.otherIndex observational study
dc.subject.otherIndex percutaneous coronary intervention
dc.subject.otherIndex retrospective study
dc.subject.otherIndex revascularization
dc.subject.otherIndex treatment duration
dc.subject.otherIndex Aged
dc.subject.otherIndex Alabama
dc.subject.otherIndex Antithrombins
dc.subject.otherIndex Aspirin
dc.subject.otherIndex Dose-Response Relationship, Drug
dc.subject.otherIndex Female
dc.subject.otherIndex Hemorrhage
dc.subject.otherIndex Hirudins
dc.subject.otherIndex Humans
dc.subject.otherIndex Incidence
dc.subject.otherIndex Infusions, Intravenous
dc.subject.otherIndex Injections, Intravenous
dc.subject.otherIndex Ischemia
dc.subject.otherIndex Male
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Peptide Fragments
dc.subject.otherIndex Percutaneous Coronary Intervention
dc.subject.otherIndex Platelet Aggregation Inhibitors
dc.subject.otherIndex Recombinant Proteins
dc.subject.otherIndex Retrospective Studies
dc.subject.otherIndex Severity of Illness Index
dc.subject.otherIndex Surgical Procedures, Elective
dc.subject.otherIndex Thrombosis
dc.subject.otherIndex Ticlopidine
dc.subject.otherKeywordPlus
dc.subject.otherWOS


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account